Chemistry:Lenvervimab: Difference between revisions
From HandWiki
(link) |
(No difference)
|
Latest revision as of 12:30, 14 February 2024
Short description: Monoclonal antibody
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Humanized |
| Target | hepatitis B virus surface antigen |
| Clinical data | |
| Other names | GC1102 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| UNII | |
Lenvervimab (INN;[1] development code GC1102) is a monoclonal antibody that is being investigated for hepatitis B.[2]
This drug is being developed by GC Pharma. (As of 2018), lenvervimab is undergoing Phase II/III trials.
References
- ↑ World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 118". WHO Drug Information 31 (4). https://www.who.int/medicines/publications/druginformation/innlists/PL117.pdf.
- ↑ "A recombinant human immunoglobulin with coherent avidity to hepatitis B virus surface antigens of various viral genotypes and clinical mutants". PLOS ONE 15 (8): e0236704. 2020. doi:10.1371/journal.pone.0236704. PMID 32790777. Bibcode: 2020PLoSO..1536704J.
 |  |
